Wealth Enhancement Advisory Services LLC Sells 6,219 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Wealth Enhancement Advisory Services LLC trimmed its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 57.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,541 shares of the company's stock after selling 6,219 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inspire Medical Systems were worth $723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of INSP. Huntington National Bank boosted its position in Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after purchasing an additional 121 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Inspire Medical Systems by 356.5% in the first quarter. Parallel Advisors LLC now owns 210 shares of the company's stock valued at $33,000 after buying an additional 164 shares during the period. True Wealth Design LLC lifted its position in shares of Inspire Medical Systems by 39.0% during the 4th quarter. True Wealth Design LLC now owns 196 shares of the company's stock valued at $36,000 after buying an additional 55 shares during the last quarter. Harbour Investments Inc. grew its stake in shares of Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after acquiring an additional 99 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after acquiring an additional 291 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus lowered their price objective on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. KeyCorp lowered their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Wells Fargo & Company cut their price objective on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Morgan Stanley lowered their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Finally, Robert W. Baird increased their target price on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $211.91.

Inspire Medical Systems Trading Down 1.8%

Shares of Inspire Medical Systems stock traded down $2.34 during trading on Friday, hitting $128.39. The stock had a trading volume of 301,417 shares, compared to its average volume of 551,519. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $225.00. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 59.16, a P/E/G ratio of 2.00 and a beta of 1.25. The business's 50-day moving average is $142.27 and its 200 day moving average is $163.94.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 10.00% and a net margin of 7.92%. The business had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. During the same period in the prior year, the company earned ($0.34) EPS. The company's quarterly revenue was up 22.7% compared to the same quarter last year. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Insider Buying and Selling

In other news, Director Shawn Mccormick sold 360 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total transaction of $57,600.00. Following the sale, the director owned 24,046 shares in the company, valued at approximately $3,847,360. This trade represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.10% of the stock is currently owned by corporate insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.